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CLINICAL RESEARCH

Impact of Acute Kidney Injury and CKD
on Adverse Outcomes in Critically Ill Septic
Patients
Javier A. Neyra1,2,3,8, Federica Mescia2,4,8, Xilong Li5, Beverley Adams-Huet2,5,
Lenar Yessayan6, Jerry Yee7, Robert D. Toto3,5 and Orson W. Moe2,3; for the Acute Kidney
Injury in Critical Illness Study Group
1
Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington,
Kentucky, USA; 2Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern
Medical Center, Dallas, Texas, USA; 3Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 4Department of Medicine, University of Cambridge School of Clinical Medicine,
Cambridge, UK; 5Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA;
6
Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA; and 7Division of Nephrology, Henry Ford Hospital,
Detroit, Michigan, USA

Introduction: Chronic kidney disease (CKD) and acute kidney injury (AKI) are strongly associated with
excess morbidity and mortality and frequently co-occur in critically ill septic patients, but how their
interplay affects clinical outcomes is not well elucidated.
Methods: We conducted a single-center, retrospective cohort study of 2632 adult patients admitted to the
intensive care unit (ICU) with severe sepsis or septic shock. Subjects were classiﬁed into 6 groups according to baseline CKD (no-CKD: estimated glomerular ﬁltration rate [eGFR] $60; CKD: eGFR 1559 ml/
min per 1.73 m2) and incident AKI by the Kidney Disease: Improving Global Outcomes (KDIGO) serum
creatinine criteria (no-AKI, AKI stage 1, AKI stages $2) during ICU stay. Study outcomes were 90-day
mortality (in hospital or within 90 days of discharge) and incident/progressive CKD.
Results: Prevalent CKD was 46% and incident AKI was 57%. Adjusted hazard ratios (95% conﬁdence intervals) for 90-day mortality relative to the reference group of no-CKD/no-AKI were 1.5 (1.12.0) in no-CKD/
AKI stage 1, 2.4 (1.93.1) in no-CKD/AKI stages$2, 1.1 (0.81.4) in CKD/no-AKI, 1.2 (0.91.6) in CKD/AKI
stage 1, and 2.2 (1.72.9) in CKD/AKI stages $2. A similar trend was observed for incident/progressive CKD
during a median follow-up of 15.3 months.
Conclusion: Stage 1 AKI on CKD was not associated with an independent increased risk of adverse outcomes in critically ill septic patients. AKI stages $2 on CKD and any level of AKI in no-CKD patients were
strongly and independently associated with adverse outcomes. Sepsis-associated stage 1 AKI on CKD may
represent distinct underlying pathophysiology, with more prerenal cases and less severe de novo intrinsic
damage, which needs further investigation.
Kidney Int Rep (2018) 3, 1344–1353; https://doi.org/10.1016/j.ekir.2018.07.016
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KI is a serious condition that affects at least 1 out of
2 critically ill patients and is associated with
adverse short- and long-term outcomes.1,2 About 50%
of patients with AKI requiring renal replacement
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therapy in the ICU die in the hospital, and AKI survivors
have an excess risk of mortality over the following
years.36 Other dire sequelae of AKI include the development and progression of CKD or end-stage renal disease.715 Conversely, CKD patients carry an elevated
risk of AKI, so that AKI and CKD predispose to each
other in a vicious circle and may exert negative impacts
independently or synergistically.1622 Approximately
30% of critically ill AKI patients have underlying
CKD.23,24 CKD by itself portends worse outcomes in hospitalized patients and is associated with a marked increase in the long-term risk of death and
cardiovascular events.2527
Kidney International Reports (2018) 3, 1344–1353
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Both AKI and CKD confer adverse prognosis; however, whether and how their coexistence affects outcomes has not been well elucidated. In several
observational studies, AKI on CKD patients were found
unexpectedly to have better in-hospital outcomes than
their counterparts with AKI but without CKD,
including shorter length of hospital stay and lower
mortality rates.2832 As for long-term outcomes in AKI
survivors, pre-existing CKD has been associated with
higher risk of progression to end-stage renal disease
and death.3236 Nevertheless, the great majority of
these studies adopted heterogeneous, nonconsensus
deﬁnitions of AKI, and did not take into account the
severity of AKI episodes, thus making it difﬁcult to
fully appreciate the prognostic impact of AKI on CKD
for clinical practice and research purposes.
The objective of our study was to examine how the
combination of prevalent CKD and incident AKI, deﬁned
by the KDIGO criteria and stratiﬁed by AKI severity,37
are related to short- and long-term outcomes in critically ill septic patients, a setting in which both CKD and
AKI are common and overall prognosis is dismal.3841
METHODS
Population and Variables
We conducted a single-center, retrospective cohort study
of patients admitted to the ICU in an urban tertiary care
hospital. The observation period was from May 2007 to
April 2012. Clinical variables were extracted from electronic health records (EHRs) and validated through
comprehensive individual review of 10% of EHRs by
data management personnel blinded to the study.
The analysis included adult ($18 years old) patients
who were admitted to the ICU with a diagnosis of severe sepsis or septic shock, deﬁned on the basis of
International Classiﬁcation of Disease, 9th Revision,
Clinical Modiﬁcation (ICD-9-CM) codes, as per the
criteria of Angus et al.,42 and had at least 1 serum
creatinine (sCr) measurement during the 3 months prior
to the index hospitalization. The closest sCr >1 day
and <3 months before the index hospitalization was
used to calculate the baseline estimated glomerular
ﬁltration rate (eGFR) through the 4-variable Modiﬁcation of Diet in Renal Disease (MDRD) study equation.43
A cutoff of 60 ml/min per 1.73 m2 eGFR was used to
deﬁne CKD at baseline (eGFR $60 ml/min per 1.73
m2 ¼ no-CKD; eGFR <60 ml/min per 1.73 m2 ¼ CKD).
Patients with end-stage renal disease or baseline
eGFR <15 ml/min per 1.73 m2 were excluded. AKI was
deﬁned as $26.4 mmol/l (0.3 mg/dl) or 50% increase in
sCr from baseline to the peak value during the ICU stay
and was graded according to KDIGO SCr criteria.37
Patients were then classiﬁed as no-AKI, AKI 1 (AKI
stage 1), or AKI $2 (AKI stage 2 or 3).
Kidney International Reports (2018) 3, 1344–1353
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Comorbidities were identiﬁed through ICD-9-CM
codes, except anemia, which was deﬁned as admission hematocrit <39% for men and <36% for women.
Data regarding drug exposure (within 72 hours of ICU
stay), red blood cell transfusion (within 72 hours of ICU
stay), and mechanical ventilation during ICU stay were
derived from hospital billing codes. Scores of critical
illness severity (Sequential Organ Failure Assessment
[SOFA]44 and Acute Physiology and Chronic Health
Evaluation II [APACHE II]45) scores were calculated on
the basis of clinical and laboratory data within the ﬁrst
24 hours of ICU admission. The SOFA score was
expressed as “nonrenal SOFA,” equivalent to the SOFA
score minus the points attributed for renal function.
Study Outcomes
Two outcomes were evaluated: (i) 90-day mortality,
deﬁned as all-cause mortality during the index hospitalization or up to 90 days following hospital discharge,
as captured from EHRs; and (ii) incident/progressive
CKD, determined by comparing baseline eGFR (before
index hospitalization) with the follow-up eGFR derived
from the mean of the last 2 sCr measurements (91% of
subjects) or last sCr measurement (9% of subjects)
available in the EHRs, and obtained at least 90 days
after hospital discharge. The deﬁnitions of incident and
progressive CKD were adapted from the ones proposed
in the Assessment, Serial Evaluation, and Subsequent
Sequelae of Acute Kidney Injury (ASSESS-AKI)
Study.46 Speciﬁcally, incident CKD was deﬁned in noCKD patients who had a reduction in eGFR of at least
25% relative to baseline and reached an eGFR <60 ml/
min per 1.73 m2. Progressive CKD was deﬁned in patients with pre-existent CKD as a decrease in eGFR of at
least 50% relative to baseline or progression to CKD
Stage 5 (eGFR <15 ml/min per 1.73 m2). The documentation of renal replacement therapy sessions reported in the EHRs during the follow-up period was
adopted as an alternative criterion to adjudicate incident or progressive CKD. Death events were also
captured from the EHRs.
Statistical Analyses
Study subjects were classiﬁed into 6 groups according
to baseline eGFR (no-CKD, CKD) and AKI status during
the ICU stay (no-AKI; AKI Stage 1; AKI Stages $2).
Categorical data were reported as percentages, and
continuous variables as mean  SD or median
(25th75th percentile) according to data distribution.
Comparisons between groups for categorical variables
were made using the Fisher exact test. Continuous
variables were compared with analysis of variance and
model pairwise contrasts or with KruskalWallis tests
as per data distribution. Trends of variables across AKI
1345
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categories were tested by JonckheereTerpstra and
CochranArmitage trend tests for continuous and
categorical variables, respectively. Two-sided P
values <0.05 were considered statistically signiﬁcant.
The CKD/AKI groups were modeled as categorical
predictors for study outcomes in Cox regression hazard
models. The interaction between CKD and AKI was
assessed for both study outcomes and, since a signiﬁcant interaction (AKICKD) was identiﬁed for 1 of the
study outcomes (incident/progressive CKD, P ¼ 0.079),
we present all models using the no-CKD/no-AKI group
as the reference group for comparison to the other 5
groups. The interaction between SOFA score and CKD/
AKI groups was nonsigniﬁcant for both study outcomes. The proportional hazards assumption was
satisﬁed for all study outcomes and tested by interaction of time and predictor and graphic assessment.
Candidate variables tested as confounders included
demographic data, comorbidity-related factors, and indicators of critical illness severity. Two multivariable
models were generated. Model 1 included the following
variables: age, gender, race; the presence of diabetes,
systolic heart failure and anemia; nonrenal SOFA score,
the need for mechanical ventilation; the exposure to red
blood cell transfusion or statins, and the length of
hospital stay (the latter only for the outcome of incident/
progressive CKD). Model 2 included variables deemed of
particular clinical relevance (age, gender, race, diabetes),
together with additional variables that were retained
through backward selection (cut-off for retention: P <
0.10). In the event of collinearity between variables
(SOFA and APACHE II scores), only 1 of 2 variables was
included. Data analysis and ﬁgures were generated using SAS 9.4 (SAS Institute, Cary, NC) and GraphPad
Prism 6.0 (GraphPad Software, La Jolla, CA).
Sensitivity Analyses
Examination of AKI Stage 1 Based on Absolute and
Relative Changes in sCr

We reclassiﬁed cases of AKI stage 1 into 2 groups: (i) AKI
1-absolute: patients who had an absolute increase in
sCr $26.4 mmol/l (0.3 mg/dl) from baseline and only a
relative increase in sCr <1.5 times baseline; and (ii) AKI 1relative: patients with a relative increase in sCr 1.5 to 1.9
times baseline, independently of absolute sCr changes.
When combined with CKD status and the other AKI
groups, this reclassiﬁcation of AKI stage 1 cases resulted
in 8 CKD/AKI groups. These groups were used as categorical predictors for study outcomes in Cox regression
hazard models, similarly to our primary analysis.
Examination of Potential Misclassiﬁcation of AKI as
CKD When Assessing CKD Outcome

We evaluated the reclassiﬁcation of the CKD outcome
when single last sCr versus the mean of the last 2 sCr
1346
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measurements was used in patients with follow-up sCr
measurements <7 days apart. We excluded the
reclassiﬁed patients from the analysis in addition to
patients with the upper and lower 2.5% of the distribution for percentage change in follow-up eGFR from
baseline to avoid implausible extrapolation of associations at the extremes of the distribution where statistical power was lower.
RESULTS
Clinical Characteristics
Figure 1 details how the cohort was generated. Of the
2632 patients included in the current analysis, 46%
had baseline CKD and 57% developed AKI during the
ICU stay. Within the CKD group, 77.8% of cases had a
baseline eGFR between 30 and 60 ml/min per 1.73 m2.
The overall incidence of AKI was similar in patients
with and without baseline CKD (56% vs. 58%,
respectively, P ¼ 0.252).
Clinical characteristics of patients, stratiﬁed by the 6
CKD/AKI groups, are summarized in Table 1. The
severity of AKI $2 was distributed as follows: 264
patients (34.3%) had AKI stage 2, 268 (34.8%) had
stage 3, and 238 (30.9%) had stage 3 requiring renal
replacement therapy. Relative to no-CKD, CKD subjects were older and more frequently had diabetes.
Exposure to i.v. or intra-arterial iodinated contrast and
aminoglycosides was signiﬁcantly lower in CKD patients. In contrast, CKD patients were more likely to be
prescribed diuretics and statins. The need for vasoactive drugs (pressors or inotropes) and for mechanical
ventilation support and indexes of severity of illness
increased in parallel with presence and severity of
AKI, both in no-CKD and in CKD patients. There were
no major differences in critical illness severity indicators between groups with the same AKI status,
either with or without baseline CKD (Table 1).
Ninety-Day Mortality Outcome
The crude 90-day mortality rate was 26.7%. Crude
mortality proportions and time-to-event analysis in the
6 CKD/AKI study groups are shown in Table 2 and
Figure 2, respectively. The 90-day mortality was lowest
in the no-CKD/no-AKI group (17.4%), closely followed,
in ascending order, by CKD/no-AKI (19.7%), CKD/AKI
1 (22.5%), and no-CKD/AKI 1 (25.6%). Groups with
AKI $2, either with or without CKD, had the highest
mortality, which was above 40% in both groups
(Table 2).
After multivariable adjustment for demographic and
clinical variables relative to the reference group of noCKD/no-AKI, the risk for 90-day mortality signiﬁcantly
increased in a stepwise incremental fashion according
to the presence and severity of AKI in the no-CKD
Kidney International Reports (2018) 3, 1344–1353
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Figure 1. Study cohort derivation. AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; ESRD,
end-stage renal disease; ICU, intensive care unit; sCr, serum creatinine.

groups (Table 3 and Figure 3a). The CKD/no-AKI and
CKD/AKI 1 groups were associated with a slight, but
statistically non-signiﬁcant, increase in the risk of
90-day mortality. Importantly, the risk for 90-day
mortality signiﬁcantly increased in the CKD/AKI $2
group (adjusted hazard ratio ¼ 2.23, 95% conﬁdence
interval ¼ 1.712.91), similarly to the corresponding
no-CKD counterparts (adjusted hazard ratio ¼ 2.45,
95% conﬁdence interval ¼ 1.923.12) (Table 3).
Other variables independently associated with 90day mortality were age, nonrenal SOFA score $4,
mechanical ventilation, anemia at ICU admission (all
positive associations), and statin exposure in the ﬁrst
72 hours of ICU stay (negative association) (Table 3).
Incident/Progressive CKD Outcome
Follow-up sCr was available in 1235 patients, corresponding to 64.0% of ICU survivors at 90 days postdischarge. Median follow-up time was 15.3 (5.729.2)
months. The proportions of the incident/progressive
CKD outcome and the corresponding adjusted hazard
ratios for the CKD/AKI groups, in reference to no-CKD/
no-AKI, are summarized in Tables 2 and 4 and
Figure 3b.
Similar to the 90-day mortality outcome, in patients
without baseline CKD, the risk for incident CKD
increased in a stepwise fashion by AKI severity. In the
presence of pre-existing CKD, however, the risk of
progressive CKD was signiﬁcantly higher only in
patients with AKI $2 (Table 4, Figure 3b). Factors
Kidney International Reports (2018) 3, 1344–1353

independently associated with incident/progressive
CKD were nonrenal SOFA $4 and anemia at ICU
admission (all positive associations) (Table 4). Crude
mortality during follow-up was 6.5% and 9.3% among
patients with and without baseline CKD, respectively.
Sensitivity Analyses
Examination of AKI Stage 1 Based on Absolute and
Relative Changes in sCr

We reclassiﬁed patients with AKI stage 1 into 2 groups
according to whether they met the criterion of relative
increase in sCr 1.5 to 1.9 times baseline (AKI 1-relative)
or not (AKI 1-absolute). The main purpose of this
sensitivity analysis was to test whether, in the presence
of baseline CKD, the 2 groups of stage 1 AKI were
differentially associated with study outcomes. Similar to
our primary analysis, the adjusted hazard ratios (95%
conﬁdence intervals) for 90-day mortality were 1.16
(0.821.64) and 1.25 (0.841.85) in CKD/AKI 1-absolute
and CKD/AKI 1-relative, respectively (reference noCKD/no-AKI). Concordant ﬁndings were observed for
incident/progressive CKD. The complete results are reported in Supplementary Tables S1 and S2.
Examination of Potential Misclassiﬁcation of AKI as
CKD When Assessing CKD Outcome

We found that only 10 patients had 2 follow-up SCr
measurements <7 days apart and were reclassiﬁed in
relation to their CKD outcome if single last SCr or the
mean of the last 2 sCr measurements was used. After
excluding these 10 patients in addition to patients with
1347
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Table 1. Demographic and clinical characteristics of the study cohort by the 6 CKD/AKI groups
Characteristics

no-CKD/no-AKI
n [ 598

no-CKD/AKI 1
n [ 363

no-CKD/AKI‡2
n [ 460

CKD/no-AKI
n [ 537

CKD/AKI 1
n [ 364

CKD/AKI ‡2
n [ 310

61.8  16.5

64.4  16.0a

61.2  15.3

70.5  14.6b,c

70.8  14.3b,c

66.9  14.1b,c,d

Demographics
Age, yr

45.1

b,c

Men, %

55.9

60.1

56.5

African American, %

41.5

43.8

50.3a,d

33.1a,f

46.4

80 (71–97)

88 (71–97)a

80 (62–97)

141 (115–186)b,c

a,c

58.1e

34.9a,f

43.2d,f

Comorbidities
Baseline sCr, mmol/l
2

Baseline eGFR, ml/min per 1.73 m

a

150 (124–221)b,c
39.6 (28.1–50.7)b,c

80.7 (69.1–94.9)

17.1

23.1a

18.0

25.7b,c

26.4b

25.2a,f

Systolic heart failure, %

3.0

4.7

1.7

2.6

4.1

5.2f

89.7

86.4

44.7 (37.4–51.3)

b,c

84.5 (70.8–105.1)

a

41.5 (30.3–50.6)

133 (115–168)b,c

Diabetes, %
Anemia, %

88.1 (70.8–110.5)

b,c

90.0

a,f

85.5

82.4

88.3

Diureticsg, %

39.5

53.2b

40.4

48.6a,f

55.8b

47.4a,f

Statinsg, %

26.8

30.6

19.8a,d

35.9b,c

42.9b,c

30.0f

33.6

b,e

b,c

b,c

Drug exposure

g

Iodine contrast , %

34.3

g

Aminoglycosides , %

20.4

11.5

12.4

11.5

3.3

5.7

21.8b,e

2.8  5.4

3.5  6.6

21.2

15.9

a,f

14.8b,d,f

a,f

6.5

6.1a,f

6.3

Critical illness indicators
Oliguria, %
CFB at 72 h, L
LOS, d

12 (7–22)
g

a

11 (6–18)

7.3  7.7

13 (7–24)
b,e

9.3b

5.4
b,e

2.8  5.6
a,f

12 (7–20)

32.2b,e,f

2.6  6.0
b

11 (6–18)

6.1  8.5b,e,f
15 (7–26)d

a

50.3b,e
48.4a,e

Pressors or inotropes , %

28.8

34.4

51.3

27.7

35.4

Mechanical ventilation, %

38.1

43.0

52.6b,e

35.6

40.1

RBC transfusiong, %

3.2

3.3

3.5

3.5

2.7

2.9

11.2  6.2

12.2  6.2a

14.3  7.2b,e

12.3  5.9a,f

13.4  6.5b,f

15.6  7.8b,f,e

3 (1–6)

4 (2–7)b

6 (3–9)b,e

4 (2–6)a,f

4 (2–7)b

6 (3–10)b,e

APACHE II
Nonrenal SOFA

APACHE II, Acute Physiology and Chronic Health Evaluation II; CFB, cumulative ﬂuid balance; eGFR, estimated glomerular ﬁltration rate; LOS, length of stay in the hospital; RBC, red
blood cell; sCr, serum creatinine; SOFA, Sequential Organ Failure Assessment.
Data are presented as mean  SD, median (25th–75th percentile), or percentage. APACHE II and nonrenal SOFA scores were calculated with data from the ﬁrst 24 hours of ICU stay.
a
Significant difference (P < 0.05) relative to reference group no-CKD/no-AKI.
b
Significant difference (P < 0.001) relative to reference group no-CKD/no-AKI.
c
Significant difference (P < 0.001) between the CKD group and the correspondent no-CKD group with the same AKI status (CKD/no-AKI vs. no-CKD/no-AKI; CKD/AKI 1 vs. no-CKD/AKI 1;
CKD/AKI $2 vs. no-CKD/AKI $2).
d
Significant P for trend (P < 0.05) across the different AKI status groups, either in no-CKD or CKD (trend across no-CKD/no-AKI, no-CKD/AKI 1 and no-CKD/AKI $2 or across CKD/no-AKI,
CKD/AKI 1 and CKD/AKI $2).
e
Significant P for trend (P < 0.001, respectively) across the different AKI status groups, either in no-CKD or CKD (trend across no-CKD/no-AKI, no-CKD/AKI 1 and no-CKD/AKI $2 or
across CKD/no-AKI, CKD/AKI 1 and CKD/AKI $2).
f
Significant difference (P < 0.05) between the CKD group and the correspondent no-CKD group with the same AKI status (CKD/no-AKI vs. no-CKD/no-AKI; CKD/AKI 1 vs. no-CKD/AKI 1;
CKD/AKI $2 vs. no-CKD/AKI $2).
g
Exposure to drugs/RBC transfusions was based on the first 72 hours of intensive care unit admission.

the upper and lower 2.5% of the distribution for percentage change in follow-up eGFR from baseline
(n ¼ 36), the multivariable analysis showed concordant
ﬁndings with our primary analysis (Supplementary
Table S3).
Table 2. Crude proportion of study outcomes stratiﬁed by the 6 CKD/
AKI groups
Group

90-Day mortality

Incident/progressive CKD

no-AKI

104/598 (17.4%)

33/321 (10.3%)

AKI 1

93/363 (25.6%)

42/183 (22.9%)

193/460 (42.0%)

51/175 (29.1%)

no-AKI

106/537 (19.7%)

24/259 (9.3%)

AKI 1

82/364 (22.5%)

20/181 (11.0%)

125/310 (40.3%)

33/116 (28.4%)

no-CKD

AKI $2
CKD

AKI $2

AKI, acute kidney injury; CKD, chronic kidney disease.
The 90-day mortality denotes all-cause death during index hospital admission or within
90 days of hospital discharge. Incident/progressive CKD (in patients without and with
baseline CKD, respectively) was adjudicated in survivors during median follow-up of
15.3 months.
1348

DISCUSSION
We studied how prevalent CKD and incident AKI
jointly affect the prognosis of critically ill patients with
sepsis. Our key ﬁnding is that, in the presence of underlying CKD, AKI stage 2 or 3, but not stage 1, was
independently associated with increased risk of 90-day
mortality and progressive CKD during the median
observation period of 15.3 months. In contrast, in patients without pre-existing CKD, the risk of 90-day
mortality and incident CKD signiﬁcantly increased in
a stepwise incremental fashion according to the stages
of AKI severity.
Previous reports have suggested that pre-existing
CKD might attenuate the adverse prognosis of patients with AKI.28,29,31,32 For instance, in the Program
to Improve Care in Acute Renal Disease (PICARD)
study, a prospective cohort of critically ill patients
with AKI, prior history of CKD was independently
associated with reduced in-hospital mortality and
Kidney International Reports (2018) 3, 1344–1353
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Figure 2. Ninety-day mortality across chronic kidney disease (CKD)/acute kidney injury (AKI) groups. For the purpose of clarity, the no-CKD and
CKD groups are represented on the left and right chart, respectively. no-CKD: baseline eGFR $60; CKD: baseline eGFR <60; no-AKI: no AKI
occurrence; AKI 1: KDIGO-sCr stage 1 AKI; AKI $2: KDIGO-sCr stage 2 or higher. ICU, intensive care unit; KDIGO, Kidney Disease: Improving
Global Outcomes; sCr, serum creatinine.

shorter length of ICU stay in AKI patients.32 Our results
seem congruent with the observation that prevalent
CKD does not signiﬁcantly worsen prognosis in critically ill patients with mild AKI. However, these ﬁndings are not fully concordant with those of other
Table 3. Multivariable models for 90-day mortality (dependent variable) in the 6 CKD/AKI groups (independent variable)
Variable

Model 1 aHR
(95% CI)

Model 2 aHR
(95% CI)

P

P

no-CKD
no-AKI

Reference

AKI 1

1.50 (1.13–1.99)

0.005

1.50 (1.13–1.98)

Reference
0.005

AKI $2

2.45 (1.92–3.12)

<0.001

2.44 (1.92–3.11)

<0.001

no-AKI

1.06 (0.81–1.40)

0.657

1.07 (0.82–1.41)

0.609

AKI 1

1.19 (0.89–1.60)

0.238

1.19 (0.89–1.60)

0.245

AKI $2

2.23 (1.71–2.91)

<0.001

2.22 (1.70–2.89)

<0.001
<0.001

CKD

Age, per 1 yr

1.02 (1.01–1.03)

<0.001

1.02 (1.01–1.03)

African American

0.88 (0.75–1.02)

0.098

0.89 (0.76–1.04)

0.127

Male gender

1.08 (0.93–1.26)

0.325

1.08 (0.93–1.26)

0.321

Diabetes

0.89 (0.74–1.08)

0.239

0.89 (0.74–1.08)

0.239

Systolic heart failure

0.68 (0.43–1.09)

0.111

—

Anemia

1.29 (1.01–1.66)

0.046

1.29 (1.00–1.65)

0.049

Nonrenal SOFA $4

1.38 (1.16–1.66)

<0.001

1.39 (1.16–1.66)

<0.001

2.21 (1.87–2.60)

<0.001

Mechanical ventilation

2.22 (1.88–2.62)

<0.001

RBC transfusion

1.32 (0.89–1.99)

0.171

Exposure to statins

0.68 (0.57–0.81)

<0.001

—
0.67 (0.56–0.80)

<0.001

APACHE II score was not included in the models due to collinearity with the SOFA
score; aHR, adjusted hazard ratio; AKI, acute kidney injury; APACHE II, Acute Physiology
and Chronic Health Evaluation II; CI, conﬁdence interval; CKD, chronic kidney disease;
RBC, red blood cell; SOFA, Sequential Organ Failure Assessment.
Data are aHRs and 95% CIs for 90-day mortality by Cox proportional hazard regression.
Model 1 includes all tested variables, whereas model 2 includes variables of deemed
particular clinical relevance (age, race, gender, diabetes), together with additional
variables that were retained through backward selection (cut-off for retention:
P < 0.10).
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studies. For example, Thakar et al. described a cohort
of more than 30,000 subjects undergoing elective or
emergent cardiac surgery and, after adjustment for
confounders, found that AKI patients with underlying
CKD had a higher risk of hospital mortality than those
without CKD.47 It is interesting that in that cohort, any
degree of CKD, independently of AKI, conferred an
excess risk of mortality. On the contrary, we found that
prevalent CKD without incident AKI was not independently associated with an increased risk of 90-day
mortality. This divergence could be due to differences in the study populations, with CKD per se playing a key role in more stable cardiac surgery patients
but a less relevant role in our cohort of critically ill
septic patients (2.2% vs. 26.7% all-cause mortality,
respectively).
Another study reporting CKD/AKI-associated outcomes was conducted in more than 43,000 hospitalized
patients in Canada.48 Notably, prevalent CKD without
incident AKI was found to be independently associated
with in-hospital mortality, but only in patients with
baseline eGFR <30 ml/min per 1.73 m2. This may help in
interpreting our ﬁndings, as only one-fourth of our CKD
patients had a baseline eGFR <30 ml/min per 1.73 m2,
possibly attenuating the putative association. Similar to
our study, the authors reported that the risk of inhospital mortality for AKI patients with pre-existing
CKD was similar or lower than their counterparts
with the same AKI severity, but no CKD.48 However,
discrepant with our analysis is that stage 1 AKI was
associated with excess risk of in-hospital mortality
1349
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Figure 3. Adjusted hazard ratios (aHRs) for study outcomes. Summary of adjusted hazard ratios (dots) and 95% conﬁdence intervals (lines) for
(a) 90-day mortality (model 1) and (b) incident/progressive chronic kidney disease (CKD) (model 1). no-CKD: baseline eGFR $60; CKD: baseline
eGFR <60; no-AKI: no AKI occurrence; AKI 1: KDIGO-sCr stage 1 AKI; AKI $2: KDIGO-sCr stage 2 or higher. AKI, acute kidney injury; KDIGO,
Kidney Disease: Improving Global Outcomes; sCr, serum creatinine.

across all strata of baseline eGFR. It is possible that the
smaller sample size of our study limited statistical power and the ability to detect small effects. Alternatively, our ﬁndings might suggest that the prognostic
impact of stage 1 AKI is attenuated in patients with
underlying CKD. This phenomenon may be speciﬁc to
critically ill septic patients, as opposed to a generic
group of hospitalized patients in the Canadian study.48
Interestingly, the analysis of the outcome of incident
or progressive CKD during the median observation
period of 15.3 months revealed a pattern similar to the
90-day mortality outcome. In patients without prevalent CKD, any level of AKI worsened outcomes in a
stepwise incremental fashion according to AKI
severity, whereas in the presence of baseline CKD, only
AKI stage 2 or above conferred a signiﬁcant excess in
risk. These ﬁndings reinforce the notion that, in the
setting of severe sepsis or septic shock, the diagnosis of
stage 1 AKI, when superimposed on CKD, did not
signiﬁcantly worsen prognosis, in either the short- or
long-term follow-up. One explanation for this is that,
in the presence of CKD, the deﬁnition of stage 1 AKI
may capture erratic oscillations in sCr of limited clinical
signiﬁcance. This was shown to be the case in a cohort
of hospitalized veterans, in which an increase in sCr of
26.4 to 35.2 mmol/l (0.30.4 mg/dl) during hospital
admission was associated with excess in-hospital
mortality only in patients with baseline eGFR above
30 ml/min per 1.73 m2, but not in those with CKD
stages 4 to 5.49 Similarly, Lin et al. demonstrated that,
in the setting of higher baseline sCr levels, the inherent
biological and laboratory variation in sCr measurement
contributes to a substantial rate of false-positive cases
1350

of AKI, especially when the criterion of absolute
increase in sCr is applied to deﬁne AKI.50 However, our
sensitivity analysis suggests that the use of absolute sCr
increases to classify AKI stage 1 did not inﬂuence our
ﬁndings.
Table 4. Multivariable models for incident/progressive CKD
(dependent variable) in the 6 CKD/AKI groups (independent variable)
Variable

Model 1 aHR
(95% CI)

p

Model 2 aHR
(95% CI)

P

no-CKD
no-AKI

Reference

AKI 1

2.11 (1.33–3.35)

0.001

2.13 (1.34–3.37)

Reference
0.001

AKI $2

2.72 (1.74–4.25)

<0.001

2.79 (1.79–4.34)

<0.001

no-AKI

0.92 (0.54–1.58)

0.769

0.94 (0.55–1.61)

0.835

AKI 1

0.95 (0.54–1.67)

0.863

0.96 (0.54–1.68)

0.878

AKI $2

2.21 (1.35–3.64)

0.002

2.33 (1.43–3.80)

<0.001

Age, per 1 yr

1.01 (1.00–1.02)

0.093

1.01 (1.00–1.02)

0.112

African American

1.28 (0.97–1.71)

0.083

1.28 (0.96–1.70)

0.087

CKD

Male gender

0.98 (0.74–1.30)

0.880

0.98 (0.74–1.29)

0.867

Diabetes

0.98 (0.71–1.36)

0.924

0.98 (0.71–1.36)

0.921

Systolic heart failure

0.85 (0.40–1.82)

0.678

—

Anemia

1.87 (1.10–3.18)

0.021

1.88 (1.11–3.19)

0.019

Nonrenal SOFA $4

1.57 (1.14–2.15)

0.005

1.48 (1.11–1.98)

0.008

Mechanical ventilation

0.83 (0.60–1.15)

0.259

—

RBC transfusion

0.87 (0.35–2.13)

0.760

—

LOS, per 1 d

1.11 (0.81–1.51)

0.505

—

Exposure to statins

0.93 (0.69–1.27)

0.671

—

APACHE II score was not included in the models due to collinearity with the SOFA
score; aHR, adjusted hazard ratio; AKI, acute kidney injury; APACHE II, Acute Physiology
and Chronic Health Evaluation II; CI, conﬁdence interval; CKD, chronic kidney disease;
LOS, length of stay in the hospital; RBC, red blood cells; SOFA, Sequential Organ Failure
Assessment.
Data are aHRs and 95% CIs for incident/progressive CKD by Cox proportional hazard
regression. Model 1 included all tested variables, while model 2 includes variables of
deemed particular clinical relevance (age, race, gender, diabetes), together with
additional variables that were retained through backward selection (cut-off for retention: P < 0.10).
Kidney International Reports (2018) 3, 1344–1353
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An alternative explanation is that, in the setting of
sepsis, AKI on CKD, speciﬁcally stage 1 AKI, is pathophysiologically distinct from that found in patients
without underlying CKD. Transient renal hypoperfusion frequently occurs in sepsis and is likely to
result in appreciable increases in sCr in patients with
CKD who already have diminished renal reserve. In
contrast, transient renal hypoperfusion can remain
subclinical in subjects with well-preserved baseline
renal function. Therefore, cases of stage 1 AKI on CKD,
compared with their counterparts without CKD, may
reﬂect lesser degrees of underlying renal/systemic
injury and entail a greater component of prerenal
pathophysiology, with limited or no de novo intrinsic
renal damage. An additional observation supporting
this hypothesis was made by Kellum et al. when they
reported that patients with sepsis-associated AKI who
recover partial or complete renal function had longterm survival similar to that in patients without
AKI.51 Interestingly, experimental data suggest that
pre-existing CKD could limit further kidney damage in
response to renal insults, which could also contribute
to mitigate post-AKI outcomes in CKD patients.52,53 For
instance, following an ischemia/reperfusion challenge,
rats that had undergone a signiﬁcant ablation of renal
mass developed a blunted degree of acute tubular necrosis and less parenchymal inﬁltration by inﬂammatory cells, compared to control animals with normal
kidneys.53 It has been proposed that this may be the
result of complex pathophysiological adaptations that
occur in the setting of chronically reduced nephron
mass, culminating in a protective inﬂuence of prior
kidney injury on acute parenchymal damage.54 As
shown by measurement55 or modeling,56 chronically
low GFR and corresponding low tubular Naþ reabsorption reduce O2 consumption in the kidney, and
potentially protect it from ischemia. It is also possible
that pre-existing kidney damage may favorably alter
the response to sepsis-associated renal injury to a
greater extent than to other nephrotoxic insults.
However, the current understanding of CKD-related
renal adaptations is still very limited, and this remains merely a hypothesis at present.
Our study has several strengths. Unlike most of the
previous analyses focusing on the joint prognostic effects of CKD and AKI, we adopted a consensus sCr-based
deﬁnition of AKI and incorporated AKI severity in the
analysis, which makes our results more relevant to
clinical practice. Another asset is that we did not only
examine 90-day mortality, but also considered adverse
renal outcomes over a prolonged follow-up period.
Finally, we performed sensitivity analyses to examine
the differential effect of absolute and relative changes in
Kidney International Reports (2018) 3, 1344–1353

sCr (used to deﬁne AKI stage 1) on study outcomes and
to address the potential misclassiﬁcation of AKI as CKD
when assessing the CKD outcome.
We also acknowledge that our study has limitations.
First, it is retrospective in nature and derived using
ICD-9-CM codes to determine sepsis diagnosis. We
relied on EHR data obtained in routine clinical care,
with the inherent possibility of selection bias and
attrition due to missing data. Second, prevalent CKD
was deﬁned on the basis of only 1 sCr measurement,
which may have led to misclassiﬁcation. Nonetheless,
we deﬁned CKD using exclusively sCr measurements
within 3 months before hospitalization and did not
consider admission sCr for the purpose of CKD determination, thus avoiding a major reason for possible
misclassiﬁcation of AKI as CKD. Third, the determination of the CKD outcome was based on 1 or 2 sCr
measurements obtained during the observation period,
which may be susceptible to misclassiﬁcation of AKI as
CKD. However, we performed sensitivity analyses to
further validate our ﬁndings. Finally, we deﬁned AKI
based only on changes in sCr and did not incorporate
the KDIGO urine output criterion. However, this is the
case also for the vast majority of other retrospective
clinical studies of AKI, and thus makes the ﬁndings
more comparable across different cohorts.
CONCLUSION
We studied how prevalent CKD and incident AKI
interact to affect outcomes in critically ill septic patients.
We found that, in the presence of pre-existing CKD, AKI
stage 1 did not signiﬁcantly increase the risk of 90-day
mortality and progressive CKD. However, AKI stage 2
or higher in those patients with baseline CKD, and each
stage of AKI in those without baseline CKD, signiﬁcantly
increased adverse outcomes. These ﬁndings raise the
hypothesis that stage 1 AKI on prevalent CKD in critically ill septic patients could reﬂect distinct AKI pathophysiology. In particular, functional or transient forms
of AKI, with a limited extent of intrinsic damage, could
be represented primarily among septic patients with
stage 1 AKI superimposed on CKD. Further collection of
comprehensive prospective clinical data characterizing
AKI severity, duration, and recovery phenotypes and
incorporating biomarker information, tissue interrogation, and novel imaging technologies will hopefully
offer fresh insights into the pathophysiology of sepsisassociated AKI and its complex interplay with CKD.
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